Open, Non Controlled, Parallel Cohorts, Multicenter, Phase 2A Study for Evaluation of the Antitumor Activity of GM102 Single Agent and in Combination With Chemotherapy in Patients With Locally Advanced Or Metastatic Colorectal Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs Murlentamab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors GamaMabs Pharma
- 30 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 30 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2019 According to a GamaMabs Pharma media release, results from the study have been presented at the ESMO World Congress on Gastrointestinal Cancer 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History